Table of Contents
Where is Biohaven Pharma located?
Biohaven Pharmaceuticals, Inc. 215 Church St New Haven, CT 06510. (203) 404-0410.
Who is the CEO of Biohaven?
Vlad Coric, M.D. – CEO and Chairman Board of Directors – Biohaven Limited | LinkedIn.
Who owns Biohaven Pharmaceuticals?
Pfizer acquired all of the outstanding shares of Biohaven not already owned by Pfizer for $148.50 per share in cash, for a total transaction consideration of approximately $11.6 billion. As a result of the acquisition, Biohaven became a wholly-owned subsidiary of Pfizer.
Is Biohaven now Pfizer?
On Tuesday, Biohaven Ltd. officially launched as a newly independent company, spun out of its former parent as part of Pfizer’s $11.6 billion acquisition, which closed on Oct. 3.
Is Biohaven a good company?
Is Biohaven Pharmaceuticals a good company to work for? Biohaven Pharmaceuticals has an overall rating of 4.4 out of 5, based on over 51 reviews left anonymously by employees. 91% of employees would recommend working at Biohaven Pharmaceuticals to a friend and 67% have a positive outlook for the business.
What is the new drug in Biohaven?
Troriluzole is one of several medicines that were spun into the new version of Biohaven following the Pfizer buyout. It previously failed trials in general anxiety disorder and Alzheimer’s disease, but is now being tested in Phase 3 studies in obsessive compulsive disorder.
What is the history of Biohaven?
The company was created in 2013 to fill what its founders saw as a void in neurology research in the pharmaceutical industry. Biohaven traces its roots to Yale, founded on intellectual property from CEO Vlad Coric, MD, Associate Clinical Professor of Psychiatry at Yale School of Medicine.
What does Biohaven sell?
Biohaven has earned its reputation as a leader in scientific innovation. Our portfolio includes treatments for a range of diseases with unmet medical needs including focal epilepsy, obsessive-compulsive disorder (OCD), spinal muscular atrophy (SMA) and more.
How many employees does Biohaven have?
Based in New Haven, CT, Biohaven Pharmaceuticals is a medium-sized health care company with 825 employees and a revenue of $462.0M.
What does Biohaven do?
“Biohaven continues to be deeply dedicated to alleviating the burden of neurological and neuropsychiatric diseases. We do this with a commitment to patients first and foremost and by resiliently following the path of scientific innovation.
What is Biohaven pharmaceutical net worth?
Interactive chart of historical net worth (market cap) for Biohaven (BHVN) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. Biohaven net worth as of December 01, 2023 is $2.7B.
Should i buy Biohaven?
Biohaven Ltd.’s analyst rating consensus is a Strong Buy.
When was Biohaven founded?
The company was created in 2013 to fill what its founders saw as a void in neurology research in the pharmaceutical industry. Biohaven traces its roots to Yale, founded on intellectual property from CEO Vlad Coric, MD, Associate Clinical Professor of Psychiatry at Yale School of Medicine.
What does Biohaven specialize in?
At Biohaven, we are harnessing the boundless potential of scientific innovation to transform the treatment of neurological and neuropsychiatric diseases, including rare disorders, while optimizing our pipeline to explore numerous therapeutic adjacencies.
What is Biohaven used for?
Biohaven has earned its reputation as a leader in scientific innovation. Our portfolio includes treatments for a range of diseases with unmet medical needs including focal epilepsy, obsessive-compulsive disorder (OCD), spinal muscular atrophy (SMA) and more.